Innsbruck,. Austria. 1046-6673/0601-O1. 10503.00/0. Journal of the. American ... American society of Nephrology treated by HD (P
Mulficenfer Study of Lipoprotein(a) and Apolipoprotein(a) Phenotypes in Patients With End-Stage Renal Disease Treated by Hemodialysis or Continuous Ambulatory Peritoneal Dialysis1 Florian
Kronenberg,2
JUrgen
Reitinger,
Paul Georg
K#{244}nig,Ulrich Pinter,
Gerd
Neyer,
Martin
Utermann,
and
Auinger, Hans
F. Kronenberg. G. Utermann. Medical Biology and Human lnnsbruck.
lnnsbruck,
P. Konig. Clinical
Innsbruck Nephrology.
U. Neyer.
Feldkirch
M. Auinger. A.
U. Lang.
of of
Hospital. Austria Feldkirch.
Hospital
Hospital.
Department
Vienna.
Vienna.
Vienna.
Karlsruhe,
Germany
Klagenfurt Soc.
(J. Am.
Hospital.
Nephrol.
1995;
Klagenfurt.
Austria
6:110-120)
ABSTRACT Numerous
have investigated Iipoprotein(a) concentrations in patients with ESRD,
studies
(Lp(a))
plasma
a patient
group
with an enormous
The reported
rosis.
differences
risk for atheroscle-
in Lp(a)
patients vary from a decrease of more than 1,000%. However, consistent, mostly because of problems analysis, and only limited data are
trols
and
increase
patients
treated
dialysis
(CAPD).
between
con-
of 49% to an data are not with statistical available for
by continuous ambulatory peritoneal To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical piffalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168)
was
conducted,
and results were compared with healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 ± 25.0 mg/dL (P < 0.005; HD) and 34.6 ± 38.4 mg/dL (P< 0.0001; CAPD) versus 18.4 results
